Skip to main content

Table 2 Factors associated with overall survival

From: Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer

Characteristics N Univariate analysis Multivariate analysis
HR 95% CI P Adjusted HR 95% CI P
Age, years
 <50 39 1 (Ref) 1 (Ref)
 ≥50 89 2.848 0.825−9.835 0.098 2.407 0.668−8.670 0.179
FIGO stage
 III 77 1 (Ref) 1 (Ref)
 IV 51 2.055 0.734−5.753 0.170 1.248 0.434−3.591 0.682
Primary treatment strategy
 PDS 79 1 (Ref) 1 (Ref)
 NAC 49 3.790 1.483−9.691 0.005 4.098 1.478−11.359 0.007
Residual tumor after PDS/IDS
 Optimal debulking 109 1 (Ref) 1 (Ref)
 Suboptimal debulking 19 1.723 0.545−5.442 0.354 1.935 0.559−6.703 0.298
BRCA status
 Wild-type 77 1 (Ref) 1 (Ref)
 Mutation 51 0.584 0.228−1.495 0.262 0.768 0.283−2.082 0.603
  1. Abbreviations: CA-125 cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, PDS primary debulking surgery, NAC neoadjuvant chemotherapy, IDS interval debulking surgery, HR hazard ratio, CI confidence interval, Ref reference